Seminar - Understanding disease heterogeneity to support development of novel infectious disease therapies
presents a seminar by:
Our research aims to better understand the molecular basis underlying patient heterogeneity to support the development of novel drugs for hospitalized S. aureus and influenza virus infections. My talk will focus on our identification of three immune correlates of disease severity: a genetic risk allele that impairs antiviral immunity, a module of serum cytokines that can regulate neutrophils, and a blood gene signature of immature neutrophils. Altered neutrophil phenotypes observed during infection have relevance to chronic inflammatory diseases such as chronic obstructive pulmonary disease and lupus. The discovery of prognostic biomarkers of severe clinical outcomes could identify patients who are most likely to benefit from novel anti-infective therapies.
The Department of Microbiology and Immunology